DE LORENZO, CLAUDIA
 Distribuzione geografica
Continente #
EU - Europa 21
AS - Asia 14
NA - Nord America 11
AF - Africa 3
Totale 49
Nazione #
US - Stati Uniti d'America 11
IT - Italia 10
VN - Vietnam 6
CN - Cina 4
CI - Costa d'Avorio 3
DE - Germania 2
FR - Francia 2
GB - Regno Unito 2
IN - India 2
NL - Olanda 2
CZ - Repubblica Ceca 1
FI - Finlandia 1
HK - Hong Kong 1
IE - Irlanda 1
PK - Pakistan 1
Totale 49
Città #
Napoli 7
Dong Ket 6
Ashburn 3
Amsterdam 2
Beijing 2
Houston 2
Aversa 1
Boardman 1
Fleming Island 1
Guangzhou 1
Helsinki 1
Kolkata 1
London 1
Naples 1
Pozzuoli 1
San Jose 1
Wuhan 1
Totale 33
Nome #
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking, file e268a72e-24aa-4c8f-e053-1705fe0a812c 18
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production, file e268a72f-5e18-4c8f-e053-1705fe0a812c 15
Long-chain polyphosphates impair SARS-CoV-2 infection and replication, file e268a733-c9f6-4c8f-e053-1705fe0a812c 7
Biological properties of a human compact anti-ErbB2 antibody., file e268a72e-8f37-4c8f-e053-1705fe0a812c 5
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma, file 794266a1-ca40-46f9-bd6c-44ddc8ca0556 1
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents, file e268a72c-c1d2-4c8f-e053-1705fe0a812c 1
Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction, file e268a72d-cc1b-4c8f-e053-1705fe0a812c 1
A novel ErbB2 epitope targeted by human antitumor immunoagents, file ee8f0618-41cd-428e-999a-4ce6ea38e3c4 1
Totale 49
Categoria #
all - tutte 222
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 222


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 1 0 0
2019/20202 0 1 0 0 0 0 1 0 0 0 0 0
2020/20214 0 0 0 0 1 0 0 0 0 0 0 3
2021/20228 3 0 0 0 0 0 4 0 1 0 0 0
2022/20237 0 0 0 0 0 0 1 1 0 2 3 0
2023/202410 0 0 3 1 0 3 0 3 0 0 0 0
Totale 49